Results 171 to 180 of about 7,807 (220)

HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells [PDF]

, 2016

core   +1 more source

National diagnostic gaps for TK2 Deficiency in Italy: insights from the AIM Multicenter Survey. [PDF]

Acta Myol
Mancuso M, Lamperti C, Musumeci O.
europepmc   +1 more source

Nucleolar FRG2 lncRNAs inhibit rRNA transcription and cytoplasmic translation, linking FSHD to dysregulation of muscle-specific protein synthesis. [PDF]

Nucleic Acids Res
Salsi V, Losi F, Fosso B, Ferrarini M, Pini S, Manfredi M, Vattemi G, Mongini T, Maggi L, Pesole G, Henras AK, Kaufman PD, McStay B, Tupler R.   +13 more
europepmc   +1 more source

Optimising the molecular investigation of the FSHD locus: an integrated workflow using single molecule optical mapping and Southern blot analysis. [PDF]

J Med Genet
Jang J, Sung H, Lee JA, Cho SI, Lee JS, Seong MW.   +5 more
europepmc   +1 more source

Single-myofiber RNA-sequencing reveals myofiber-level transcriptomic heterogeneity and DUX4 activation in FSHD muscle biopsies [PDF]

Silvère M. van der Maarel, Anita van den Heuvel, Dongxu Zheng, Svetlana Pasteuning - Vuhman, Joke Boertje - van der Meulen, E. Brouwer, Emile de Meijer, Annelot Wondergem, Susan L. Kloet   +8 more
openalex   +1 more source

Increased <i>METTL3</i> Expression and m6A Methylation in Myoblasts of Facioscapulohumeral Muscular Dystrophy. [PDF]

Int J Mol Sci
Settas N, Bittel AJ, Chen YW.
europepmc   +1 more source

Emerging preclinical animal models for FSHD

, 2015
Angela Lek, Fedik Rahimov, Peter L. Jones, Louis M. Kunkel   +3 more
openalex   +1 more source

Effect of creatine monohydrate on motor function in children with facioscapulohumeral muscular dystrophy: A multicenter, randomized, double-blind placebo-controlled crossover trial. [PDF]

Pharmacotherapy
Woodcock IR, de Valle K, Cairns A, Davidson ZE, Kean M, Varma N, Grobler A, Metz D, Carroll K, Dilek N, Heatwole C, Ryan MM, Delatycki MB, Yiu EM.   +13 more
europepmc   +1 more source

A systemically deliverable lipid-conjugated siRNA targeting DUX4 as an facioscapulohumeral muscular dystrophy therapeutic. [PDF]

Mol Ther Methods Clin Dev
Daman K, Yan J, Biscans A, Echeverria D, Shmushkovich T, Wolfson A, Alterman JF, Khvorova A, Emerson CP.   +8 more
europepmc   +1 more source

Systemic Pharmacotherapeutic Treatment of the ACTA1-MCM/FLExDUX4 Preclinical Mouse Model of FSHD [PDF]

Ngoc Lu‐Nguyen, Stuart G. Snowden, Linda Popplewell, Alberto Malerba   +3 more
openalex   +1 more source